Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Seema Gulyani"'
Autor:
Alexander Davis, Sevil Yasar, Iris Emerman, Seema Gulyani, Kristina Khingelova, Aruna Rao, Lacie Manthripragada, Mark Luciano, Abhay Moghekar
Publikováno v:
BMC Neurology, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background Presently, for patients presenting with suspected Normal Pressure Hydrocephalus (NPH) who undergo temporary drainage of cerebrospinal fluid (CSF) there is no defined model to differentiate chance improvement form clinical signific
Externí odkaz:
https://doaj.org/article/8426e86e76ce4829b2cd49b4a9952158
Autor:
Karen Bandeen-Roche, Amanda Calabro, Amanze Orusakwe, Rianne Esquivel, Kristina Khingelova, Jacqueline Darrow, Marilyn S. Albert, Abhay Moghekar, Aruna Rao, Christopher Traynham, Sara Gannon, Seema Gulyani
Publikováno v:
J Appl Lab Med
Background Cerebrospinal fluid (CSF) biomarkers are increasingly used to confirm the accuracy of a clinical diagnosis of mild cognitive impairment or dementia due to Alzheimer disease (AD). Recent evidence suggests that fully automated assays reduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7377f52940b3d31fa33eb603ad80861e
https://doi.org/10.1093/jalm/jfaa145
https://doi.org/10.1093/jalm/jfaa145
Autor:
Josephine M. Egan, Nigel H. Greig, Olga D. Carlson, Dimitrios Kapogiannis, Roger J. Mullins, Mark P. Mattson, Susan M. Resnick, Chee W. Chia, Joyce Tran, Seema Gulyani, Maja Mustapić, Yazhou Li
Publikováno v:
Curr Alzheimer Res
Background:Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP- 1) receptor agonist used for treating type 2 diabetes, is neuroprotective and disease-modifying in Alzheimer’s Disease (AD).Objective:We performed an 18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acf31e1621421741db515d59442c296a
https://doi.org/10.2174/1567205016666190913155950
https://doi.org/10.2174/1567205016666190913155950
Autor:
Lacie Manthripragada, Alexander Davis, Abhay Moghekar, Mark G. Luciano, Seema Gulyani, Sevil Yasar
Publikováno v:
Clinical neurology and neurosurgery. 207
Objective The primary aim of the study was to assess the effect comorbid Parkinson syndromes have on results of CSF tap test (TT) and shunt outcomes for patients presenting with Normal Pressure Hydrocephalus (NPH). We hypothesized that patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cddd61c8283c2ddfa2e7ad087315aeab
https://pubmed.ncbi.nlm.nih.gov/34280677
https://pubmed.ncbi.nlm.nih.gov/34280677
Autor:
Kristina Khingelova, Sevil Yasar, Iris Emerman, Lacie Manthripragada, Abhay Moghekar, Alexander Davis, Seema Gulyani, Mark G. Luciano, Aruna Rao
Publikováno v:
BMC Neurology
BMC Neurology, Vol 20, Iss 1, Pp 1-7 (2020)
BMC Neurology, Vol 20, Iss 1, Pp 1-7 (2020)
Background Presently, for patients presenting with suspected Normal Pressure Hydrocephalus (NPH) who undergo temporary drainage of cerebrospinal fluid (CSF) there is no defined model to differentiate chance improvement form clinical significance chan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2826c811dbb1edb1ffa6b60af1644b0
https://doi.org/10.1186/s12883-020-01719-y
https://doi.org/10.1186/s12883-020-01719-y
Autor:
Maja Mustapić, Dimitrios Kapogiannis, Seema Gulyani, Tom Diehl, Jessica Gill, Ramon Diaz-Arrastia, Robert S. Stern, Nicole Osier, Vida Motamedi, Rael T. Lange
Publikováno v:
Brain Injury. 32:1359-1366
OBJECTIVE: Identify biomarkers in peripheral blood that relate to chronic post-concussive and behavioural symptoms following traumatic brain injuries (TBIs) to ultimately improve clinical management. RESEARCH DESIGN: We compared military personnel wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bf8120b00e71a27bc923f59c1be7ee3
https://doi.org/10.1080/02699052.2018.1471738
https://doi.org/10.1080/02699052.2018.1471738
Publikováno v:
Sleep Medicine. 31:86-92
Dopaminergic drugs have been used as the first-line treatment for restless legs syndrome (RLS) for many years and are considered to be, at least over the short-term, effective and safe. However, the main long-term complication of dopaminergic treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70205a2c31b8584595ee4a6b3b5e8c5b
https://doi.org/10.1016/j.sleep.2016.08.019
https://doi.org/10.1016/j.sleep.2016.08.019
Autor:
Joyce Tran, Chiung-Wei Huang, Sahil Chawla, Sean T. Berkowitz, Erez Eitan, Constantine G. Lyketsos, Maja Mustapić, Michael P. Lazaropoulos, Yang An, Ryan Spangler, Esther S. Oh, Luigi Ferrucci, Dimitrios Kapogiannis, Seema Gulyani, Susan M. Resnick, Michelle Shardell, Thomas C. Diehl, Edward J. Goetzl
Publikováno v:
JAMA Neurol
Importance Blood biomarkers able to diagnose Alzheimer disease (AD) at the preclinical stage would enable trial enrollment when the disease is potentially reversible. Plasma neuronal-enriched extracellular vesicles (nEVs) of patients with AD were rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a1a4c89dc13435e396d71b271d0e3b3
https://pubmed.ncbi.nlm.nih.gov/31305918
https://pubmed.ncbi.nlm.nih.gov/31305918
Autor:
Seema Gulyani, David Tweedie, Maja Mustapić, Yazhou Li, Simon S. Skene, Dimitrios Kapogiannis, Hanuma Kumar Karnati, Sahil Chawla, Dilan Athauda, Kashfia Chowdhury, Nigel H. Greig, Thomas Foltynie
Publikováno v:
JAMA neurology. 76(4)
Importance: Exenatide, a glucagon-like peptide 1 agonist used in type 2 diabetes, was recently found to have beneficial effects on motor function in a randomized, placebo-controlled trial in Parkinson disease (PD). Accumulating evidence suggests that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67720cf13ab8bb60c37e3ad19a7e4496
https://pubmed.ncbi.nlm.nih.gov/30958554
https://pubmed.ncbi.nlm.nih.gov/30958554
Publikováno v:
Basal Ganglia. 6:165-172
Parkinson's disease is a multi-systems neurodegenerative disorder that is characterized by a combination of motor and non-motor symptoms. Non-motor symptoms of Parkinson's disease comprise a variety of cognitive, neuropsychiatric, autonomic, sensory,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac2e93a1c6479d215bc2fafe79d17c85
https://doi.org/10.1016/j.baga.2016.05.001
https://doi.org/10.1016/j.baga.2016.05.001